Cancer genetic susceptibility testing: ethical and policy implications for future research and clinical practice. Cancer Genetic Studies Consortium, National Institutes of Health.
Cancer genetic susceptibility testing: ethical and policy implications for future research and clinical practice. Cancer Genetic Studies Consortium, National Institutes of Health.
复制标题
癌症遗传易感性测试：对未来研究和临床实践的伦理和政策影响。
DOI：
10.1111/j.1748-720x.1997.tb01406.x
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Lerman,C
中科院分区：
文献类型：
--
作者：
Wilfond,BS;Rothenberg,KH;Thomson,EJ;Lerman,C
癌症易感性基因检测是生物技术的一项应用，它有可能改善人们的社会心理和身体健康，并造成重大的心理社会和身体伤害。尽管基因检测的价值不确定，但它引起了生物技术公司、研究人员、医疗保健提供者和公众的兴趣。随着更多的测试变得可行，提供测试并可报销的压力可能会增加。这些测试的好处和坏处并不在于测试本身，而在于它们预测或改变未来的能力。测试的价值并不来自于信息本身，而是来自于向患者和提供者有效传达信息的能力，以及患者、提供者和其他人对此信息的行为反应。
Genetic testing for cancer susceptibility is an application of biotechnology that has the potential both to improve the psychosocial and physical wellbeing of the population and to cause significant psychosocia1 and physical harms. In spite of the uncertain value of genetic testing, it has captured the interest of biotechnology companies, researchers, health care providers, and the public. As more tests become feasible, pressure may increase to make the tests available and reimbursable. Both the benefits and harms of these tests lie not as much in the tests themselves, as in their power to predict or alter the future. The value of the tests does not derive from the information per se, but from the ability to communicate effectively the information to patients and providers, and the behavioral responses of patients, providers, and others to this information.